

Development of a tiered screening strategy for a molecular-initiating event: thyroperoxidase inhibition



Katie Paul Friedman^{1,2}, Eric D. Watt^{1,4}, Joan M. Hedge², Kevin M. Crofton⁴, Michael W. Hornung³, Steven O. Simmons⁴ ¹Oak Ridge Institute for Science Education Postdoctoral Fellow;

²Integrated Systems Toxicology Division; ³Mid-Continent Ecology Division, NHEERL; and ⁴National Center for Computational Toxicology; ORD, U.S. EPA, RTP, NC and Duluth, MN


Simmons.Steve@epa.gov.

Abstract

Adverse outcome pathway (AOP) analyses illustrate that some molecular-initiating events (MIEs) for thyroid disruption, including thyroperoxidase (TPO) inhibition, are not evaluated by current ToxCast/Tox21 high-throughput screening (HTS) assays. A novel HTS assay for TPO inhibition was developed by adaptation of the guaiacol oxidation assay with a fluorescent peroxidase substrate (Amplex UltraRed, AUR, LifeTech) in a rat thyroid microsome-based assay optimized to 384-well format. Initial testing of the AUR-TPO assay was conducted using a 21-chemical training set that included a reference chemical, methimazole (MMI), known TPO inhibitors, and negative controls. The AUR-TPO assay signal was stable (30-120) min), the dynamic range and Z' score with MMI were 11-fold and 0.93, and the IC₅₀ for MMI was 0.025 µM (compared to 2.20 µM in a guaiacol-based 96-well assay). The ToxCast Phase I & II libraries (1060 chemicals) were tested with the AUR-TPO assay using an initial screen of one high concentration to identify candidate inhibitors. Chemicals that exceeded 20% inhibition were then screened in concentration-response (6 or 8 concentrations for Phase I & II). In addition, 2 parallel screens were conducted: ATP availability in HEK293T cells (24 hr exposure) to indicate cytotoxicity; and, luciferase inhibition to identify nonspecific protein inhibitors. Results demonstrated known and novel chemicals that inhibited TPO at concentrations below cytotoxicity and that did not inhibit luciferase. AOP-based analyses for thyroid screening enabled development of a new HTS assay that allowed screening of ToxCast chemicals for TPO inhibition. This assay provides an additional data stream to support prioritization of chemicals within the Endocrine Disruptor Screening Program. This abstract does not necessarily reflect the policy of the US EPA.

Why is thyroperoxidase (TPO) activity screening assay a critical need for integrated thyroid disruptor screening?

Benzophenone-2 isoflavones. anti-hyperthyroid drugs coal derivatives pesticides




- TPO catalyzes TH synthesis within the thyroid
- TPO is the known target of many environment
- No medium- or high-throughput assays exist for **TPO** screening


Assay principles


The existing low-throughput guaiacol assay was modified to generate the AUR-TPO assay, which is executed using 384 well-plates and is amenable to screening 100s-1000s of chemicals.

Guaiacol H₂O₂ **Peroxidase**










Assay	GUA-TPO	AUR-rTPO	
Plate format	3-8 wells of a 96 wp	384 wp	
Dynamic range (mean ± SE)	127 ± 80	11.5 ± 2.4	
Z' (mean ± SE)	0.62 ± 0.16	0.93 ± 0.021	
CV (%)	92	16.1	
MMI IC50 (μM)	2.20	0.025	
N	3	3	
Wells or tests per rat	8.3	83.3	
Reaction	Kinetic, 60 s	Endpoint,stable 30 min – 2hr	
Detection	Spectrophotometric, 450-470nm	Fluorescent, 544/590	


#		Chemical Name	Abbreviation				
1	Methimazole		MMI				
2	ica	3-Amino-1,2,4-Triazole (Amitrole)	ATR				
3	emica	2,2',4,4'-Tetrahydroxy-benzophenone	BP2	#	cipated negative	Chemical Name	Abbreviation
4	ch	Daidzein	DDZ	1		2-hydroxy-4-methoxybenzophenone	BP3
5	sitive	Ethylene thiourea	ETU	2		Dibutylphthalate	DBP
6	Sit	Genistein	GEN	3		Diethylhexylphthalate	DEHP
7	od I	2-mercaptobenzothiazole	MBT	4		Diethylphthalate	DEP
8	ipated	4-nonylphenol	4NP	5		3,5-Dimethylpyrazole-1-methanol	DPM
9	ipa	4-propoxyphenol	4POP	6	Si Ch	Iopanoic Acid	IOA
10	Antic	6-propylthiouracil	PTU	7	l j	Methyl 2-methyl-benzoate	MMB
11	Ar	Resorcinol	RSC	8	Ā	Sodium-perchlorate	NaPER
12		Sulfmethazine	SMZ	9		Triclosan	TCS

Hypothesis I: The AUR substrate can be used in a 384-well, semi-automated assay to detect TPO inhibitors (see Paul et al., 2014, Chemical Research in Toxicology).


TPO-inhibitors from the training set using rat TPO



Training set chemicals with no effect on rat TPO activity




Hypothesis II: The AUR-rTPO assay can be used to screen the ToxCast Phase I and II chemical libraries using a tiered approach.




Conclusions

- The 384-well plate AUR-TPO screening using rat thyroid microsomes confers the following advantages:
 - ➤ Stable, fluorescent signal for 30 min 2 hr
 - ➤ High reproducibility and adequate dynamic range to identify TPO inhibitors
 - ➤ 10-fold reduction in animal tissue required per well tested
 - > 500x increase in sample throughput compared to guaiacol assay
- The 21-chemical training set demonstrated that the AUR-TPO assay may be used to specifically discern TPO inhibitors. The assay demonstrated a 100% true positive rate and a 0% false negative rate. Two out of 21 chemicals were unexpected positives when compared to previous work with guaiacol.
- Use of the AUR-rTPO assay in a tiered screening strategy may increase knowledge regarding how many chemicals may inhibit TPO, and may also provide valuable endocrine disruptor screening information while supporting efforts to reduce animal use in testing.
- With ~1100 chemicals screened to date in this new AUR-TPO assay, including parallel non-specific enzyme inhibition and cytotoxicity assays, this work represents the largest screening effort to date for TPO inhibition. AUR-TPO inhibitors were structurally diverse, but many AUR-TPO inhibitors may be nonspecific; thus, use of parallel measures of specificity may provide context for further prioritization decisions.

Specificity: comparison of AUR-TPO IC20 with cytotoxicity and nonspecific protein inhibition.







~50% of hits were not structurally related. Largest bins were enriched for anilines and phenols